AC Immune Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 122

Employees

  • Stock Symbol
  • ACIU

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.94
  • (As of Friday Closing)

AC Immune General Information

Description

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • EPFL Innovation Park
  • Building B
  • 1015 Lausanne
  • Switzerland
+41 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • EPFL Innovation Park
  • Building B
  • 1015 Lausanne
  • Switzerland
+41 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AC Immune Stock Performance

As of 20-Nov-2026, AC Immune’s stock price is $1.94. Its current market cap is $194M with 99M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.94 $2.13 $1.93 - $3.90 $194M 99M 203K -$0.44

AC Immune Financials Summary

As of 30-Sep-2026, AC Immune has a trailing 12-month revenue of $24.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 172,297 185,710 83,127 409,265
Revenue 24,870 4,299 31,015 16,465
EBITDA (83,765) (58,845) (58,822)
Net Income (45,250) (84,763) (57,826) (60,331)
Total Assets 166,852 194,781 255,568 217,651
Total Debt 4,671 5,734 6,006 4,163
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AC Immune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AC Immune‘s full profile, request access.

Request a free trial

AC Immune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pi
Drug Discovery
Lausanne, Switzerland
122 As of 2025

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AC Immune Competitors (66)

One of AC Immune’s 66 competitors is Beam Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Beam Therapeutics Formerly VC-backed Cambridge, MA
Editas Medicine Formerly VC-backed Cambridge, MA
Alzinova Corporation Gothenburg, Sweden
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Lisata Therapeutics Corporation Basking Ridge, NJ
You’re viewing 5 of 66 competitors. Get the full list »

AC Immune Patents

AC Immune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4834917-A1 Targeting peptides, aav variants and uses thereof Pending 02-May-2025
WO-2026229619-A2 Targeting peptides, aav variants and uses thereof Pending 02-May-2025
WO-2026209986-A1 Fused tricyclic heterocycles having activity in preventing or decreasing tau aggregates Pending 03-Apr-2025
WO-2026190322-A1 Asc binding molecules for therapy and diagnosis Pending 13-Mar-2025
WO-2026185478-A1 Pyrazolo-pyrido-oxazine derivatives for the treatment of abnormalities associated with tau protein aggregates Pending 07-Mar-2025 A61P25/28
To view AC Immune’s complete patent history, request access »

AC Immune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AC Immune Investments (1)

AC Immune’s most recent deal was a Corporate Asset Purchase with Affiris (Vaccine Candidate PD01) for . The deal was made on 27-Jul-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Affiris (Vaccine Candidate PD01) 27-Jul-2021 Corporate Asset Purchase Buildings and Property
To view AC Immune’s complete investments history, request access »

AC Immune ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view AC Immune’s complete esg history, request access »

AC Immune FAQs

  • When was AC Immune founded?

    AC Immune was founded in 2003.

  • Where is AC Immune headquartered?

    AC Immune is headquartered in Lausanne, Switzerland.

  • What is the size of AC Immune?

    AC Immune has 122 total employees.

  • What industry is AC Immune in?

    AC Immune’s primary industry is Drug Discovery.

  • Is AC Immune a private or public company?

    AC Immune is a Public company.

  • What is AC Immune’s stock symbol?

    The ticker symbol for AC Immune is ACIU.

  • What is the current stock price of AC Immune?

    As of 20-Nov-2026 the stock price of AC Immune is $1.94.

  • What is the current market cap of AC Immune?

    The current market capitalization of AC Immune is $194M.

  • What is AC Immune’s current revenue?

    The trailing twelve month revenue for AC Immune is $24.9M.

  • Who are AC Immune’s competitors?

    Beam Therapeutics, Editas Medicine, Alzinova, Denali Therapeutics, and Lisata Therapeutics are some of the 66 competitors of AC Immune.

  • What is AC Immune’s annual earnings per share (EPS)?

    AC Immune’s EPS for 12 months was -$0.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process